My own personal liraglutide (Victoza) experiment continues. Victoza is an injectable GLP-1 medication manufactured by Novo Nordisk. It is commonly used in treatment of type-2 diabetes, but its effects seem to offer benefits for those with type-1 as well. A small study at U of Buffalo (NY) showed that adding liraglutide to an intensive insulin program can reduce appetite, insulin requirements and glucose variability. I’ve seen the reduction in appetite personally, and hence a reduction in bolus requirements. I’ve also seen a small reduction in basal insulin requirement due, presumably, to the inhibition of glucagon secretion by liraglutide.
My one concern is that I’ve had to keep increasing my dose of liraglutide in order to maintain the appetite suppression. I started out at 0.6 mcg and am now up to about 1.5 mcg (the maximum dose is 1.8). Why the constant buildup of “tolerance” to the medication? Beats me. But I’ll keep working with it to learn as much as I can and, hopefully, improve my own BG control along the way.